Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by vikingguyon May 30, 2017 9:58pm

172 Views

Post# 26303890

RE:RE:RE:Most analysts' targets are now met

What we need is confirmation of a big institution taking a position and I think we all know its coming.....we have been green for 4 or 5 days in a row and are yet again on quite a down market day.

Our due diligence has led us to a priority review designation, pdufa, acceptance of BLA by mid June and I think we are bang on.....that would explain the current run we are on in my opinion.

Bullboard Posts

Advancing flagship Ishkõday Gold Project in Ontario